Preventing colorectal cancer using a new drug in a rat model.
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
This study is looking at how well a new drug called TPST-1495 can help prevent colorectal cancer in people with Familial Adenomatous Polyposis (FAP), using a special rat model to see if it works safely and effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10927554 on NIH RePORTER |
What this research studies
This research investigates the effectiveness and safety of a drug called TPST-1495 in preventing colorectal cancer, particularly in individuals with Familial Adenomatous Polyposis (FAP). The study uses a specific rat model to assess how well this drug works and to identify any potential side effects. By analyzing the drug's impact on cancer development, researchers aim to gather important data that could lead to new treatment options for patients at risk of colorectal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a genetic predisposition to colorectal cancer, specifically those with Familial Adenomatous Polyposis (FAP).
Not a fit: Patients without a history of colorectal cancer or those not at risk due to genetic factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for patients at high risk of developing colorectal cancer.
How similar studies have performed: Similar research has shown promise in using targeted therapies for cancer prevention, indicating potential for success in this approach.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Rao, Chinthalapally — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rao, Chinthalapally
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.